140 completed, 42 unknown, 37 recruiting, 27 terminated. 127 Phase 2, 65 Phase 1, 37 Phase 3, 28 Not applicable, 3 Phase 4.
Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-08-28 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| IKS04 Regimen in Advanced Solid Tumors That Express CA242 IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody - Colorectal Cancer, Gastro Esophageal Junctional Cancer | Phase 1 | Not yet recruiting | Iksuda Therapeutics Ltd. | 120 | 2026-11-01 | 2026-07-31 |
| Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in Sohag Locality histopathology of gall bladder - Gall Bladder Carcinoma | Recruiting | Sohag University | 100 | 2026-09-20 | 2026-10-21 | |
| AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer AK112, Gemcitabine, Cisplatin - Gallbladder Cancer | Phase 2 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 22 | 2026-08-28 | 2026-08-17 |
| Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study Postoperative radiotherapy, Capecitabine or S-1 - Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 92 | 2026-06-16 | 2026-06-24 |
| A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. GV20-0251, anti-PD-1 monoclonal antibodies - Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms | Phase 2 | Not yet recruiting | GV20 Therapeutics | 227 | 2026-06-02 | 2026-06-08 |
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer Nanvuranlat, Physician's Best Choice - Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | J-Pharma Co., Ltd. | 480 | 2026-05-11 | 2026-09-29 |
| Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine - Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic | Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 18 | 2026-05-01 | 2026-05-29 |
| Outcomes After Liver and Biliary Resection at a High-Volume Center Liver Neoplasms, Hepatobiliary Diseases | Not yet recruiting | Azienda USL Toscana Centro | 1000 | 2026-04-01 | 2026-04-29 | |
| TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA) | Not yet recruiting | Aarhus University Hospital | 300 | 2026-03-15 | 2026-03-06 | |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide - Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-06-11 |
| Distance-Based Exercise to Preserve Function and Prevent Disability Exercise intervention, Telemedicine, Aerobic Exercise Intervention - Localized Malignant Solid Neoplasm, Anal Cancer | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 104 | 2026-02-11 | 2026-10-02 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2026-01-01 | 2025-11-28 |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin - Biliary Tract Cancer | Phase 3 | Recruiting | AstraZeneca | 1100 | 2025-12-04 | 2026-09-28 |
| A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer Durvalumab or Pembrolizumab, Durvalumab or Pembrolizumab + Levnatinib, Durvalumab or Pembrolizumab + Venadaparib - Biliary Tract Neoplasms, Advanced Cancer | Phase 1 / Phase 2 | Not yet recruiting | Yonsei University | 160 | 2025-12-01 | 2025-12-08 |
| Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer Trifluridine/tipiracil, Oxaliplatin - Biliary Tract Cancer, Biliary Tract Neoplasms | Phase 2 | Suspended | Case Comprehensive Cancer Center | 27 | 2025-12-01 | 2026-10-20 |
| DESTINY-PANTUMOUR04 Trastuzumab deruxtecan - Adenocarcinoma (NOS), Anal Cancer | Recruiting | AstraZeneca | 100 | 2025-09-18 | 2026-09-25 | |
| Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer Comprehensive Geriatric Assessment - Hepatobiliary Cancer, Pancreatic Cancer | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 526 | 2025-09-01 | 2025-05-31 |
| To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors XH001 Injection, mFOLFIRINOX Treatment Regimen - Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | Shenzhen Xinhe Biomedical | 48 | 2025-08-25 | 2026-05-19 |
Showing 20 of 295. Sign in to see all of them.
Cholangiocarcinoma (110) · Bile Duct Neoplasms (105) · Pancreatic Neoplasms (87) · Stomach Neoplasms (71) · Carcinoma, Hepatocellular (67) · Biliary Tract Neoplasms (62) · Colonic Neoplasms (53) · Esophageal Neoplasms (49) · Liver Neoplasms (46) · Rectal Neoplasms (41) · Neoplasms (38) · Breast Neoplasms (31) · Anus Neoplasms (30) · Colorectal Neoplasms (30)
Neoplasms by Site (295) · Digestive System Diseases (294) · Digestive System Neoplasms (293) · Biliary Tract Diseases (292) · Gallbladder Diseases (292) · Neoplasms (257) · Biliary Tract Neoplasms (233) · Neoplasms by Histologic Type (186) · Neoplasms, Glandular and Epithelial (181) · Adenocarcinoma (172) · Carcinoma (170) · Bile Duct Diseases (104) · Endocrine System Diseases (97) · Endocrine Gland Neoplasms (96) · Liver Diseases (94)
Gemcitabine (63) · Cisplatin (41) · Oxaliplatin (31) · Capecitabine (30) · Fluorouracil (22) · Leucovorin (20) · Irinotecan (12) · 130-nm albumin-bound paclitaxel (11) · pembrolizumab (11) · durvalumab (10) · Erlotinib Hydrochloride (8) · 1,2-diaminocyclohexaneplatinum II citrate (7) · Albumin-Bound Paclitaxel (7) · Bevacizumab (7) · Magnetic Resonance Spectroscopy (7)
National Cancer Institute (NCI) (28) · Memorial Sloan Kettering Cancer Center (7) · Shanghai Jiao Tong University School of Medicine (6) · Alliance for Clinical Trials in Oncology (5) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (5) · M.D. Anderson Cancer Center (5) · Centre Paul Strauss (4) · City of Hope Medical Center (4) · Mayo Clinic (4) · RenJi Hospital (4) · Tianjin Medical University Cancer Institute and Hospital (4) · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (4) · Yonsei University (4) · AstraZeneca (3) · Case Comprehensive Cancer Center (3)
United States (146) · China (58) · Germany (25) · South Korea (25) · United Kingdom (22) · France (18) · Canada (16) · Italy (16) · Spain (16) · India (15) · Japan (13) · Chile (11) · Australia (10) · Taiwan (8) · Brazil (7)
Anthony El-Khoueiry (3) · Steven R. Alberts, MD (3) · Tanios Bekaii-Saab (3) · Afshin Dowlati, MD (2) · Amit Mahipal (2) · Arndt Vogel, Prof. Dr. (2) · Benjamin Tan, M.D. (2) · Franco M. Muggia, MD (2) · Ghassan Abou-Alfa, MD (2) · Haitao Zhao, MD (2) · Hedy Kindler (2) · Herbert K. Lyerly, MD (2) · Jean L Grem, MD (2) · Jennifer Knox, M.D. (2)
PMID 20375404, PMID 32461347, PMID 38661512, PMID 42176183, PMID 11261621, PMID 12196376, PMID 12393999, PMID 12455783, PMID 12794246, PMID 12850683, PMID 15558814, PMID 16849762, PMID 16875082, PMID 18470481, PMID 18669454, PMID 18669455, PMID 19023677, PMID 19399502, PMID 19737952, PMID 20068553, PMID 20179219, PMID 20662793, PMID 20981545, PMID 21034892, PMID 21556747, PMID 22480131, PMID 23006802, PMID 24512954, PMID 24769639, PMID 24852116, PMID 25241229, PMID 25538178, PMID 25964250, PMID 26179201, PMID 26228433, PMID 26598942, PMID 26646758, PMID 26912134, PMID 27020837, PMID 27095655, PMID 27234522, PMID 27806234, PMID 28818953, PMID 29341833, PMID 29433850, PMID 29882997, PMID 30473706, PMID 30515783, PMID 30642373, PMID 30646854
2023 (6), U10CA032102 (4), N01CM00070 (3), N01CM62201 (3), P30CA015083 (3), P30CA033572 (3), P30CA068485 (3), U10CA180888 (3), 2019 (2), N01CM17104 (2), P30CA014089 (2), P30CA014599 (2), P30CA016087 (2), P30CA036727 (2), P30CA043703 (2)